4.7 Article

Future Directions in Mucormycosis Research

期刊

CLINICAL INFECTIOUS DISEASES
卷 54, 期 -, 页码 S79-S85

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir886

关键词

-

资金

  1. National Institutes of Health through MD Anderson's Cancer Center [CA016672]
  2. Henry Schueler 419 Foundation
  3. Merck Co
  4. Gilead
  5. Astellas
  6. Enzon
  7. Novartis
  8. Merck
  9. Pfizer
  10. NovaDigm Therapeutics
  11. Schering-Plough
  12. Aventis
  13. MSD

向作者/读者索取更多资源

Mucormycosis has emerged as an important opportunistic infection, especially in severely immunosuppressed hosts. The evolving epidemiology, immunopathogenesis, molecular virulence studies, early diagnosis, and pitfalls in designing clinical studies of mucormycosis are discussed in this article.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据